2017
DOI: 10.4049/jimmunol.1601716
|View full text |Cite
|
Sign up to set email alerts
|

Def6 Restrains Osteoclastogenesis and Inflammatory Bone Resorption

Abstract: Inflammatory bone resorption mediated by osteoclasts is a major cause of morbidity and disability in many inflammatory disorders, including rheumatoid arthritis (RA). The mechanisms that regulate osteoclastogenesis and bone resorption in inflammatory settings are complex and have not been well elucidated. In this study, we identify the immunoregulator Def6 as a novel inhibitor of osteoclastogenesis in both physiological and inflammatory conditions. Def6 deficiency in Def6−/− mice enhanced the sensitivity of os… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
26
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 14 publications
(27 citation statements)
references
References 60 publications
1
26
0
Order By: Relevance
“…6 ), suggesting a positive regulatory role of miR-182 in osteoclastogenesis and bone resorption under inflammatory conditions. To further test this hypothesis in vivo, we first used a well-established inflammatory calvarial osteolysis mouse model induced by TNF-α or lipopolysaccharides (LPS) 42 46 . Phosphate buffered saline (PBS) injection as a negative control did not induce resorptive pit formation on the calvarial bone surfaces (data not shown).…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…6 ), suggesting a positive regulatory role of miR-182 in osteoclastogenesis and bone resorption under inflammatory conditions. To further test this hypothesis in vivo, we first used a well-established inflammatory calvarial osteolysis mouse model induced by TNF-α or lipopolysaccharides (LPS) 42 46 . Phosphate buffered saline (PBS) injection as a negative control did not induce resorptive pit formation on the calvarial bone surfaces (data not shown).…”
Section: Resultsmentioning
confidence: 99%
“…4d ). Previous literature demonstrates that interferon pathway (IFN α, β, or γ) inhibits osteoclast differentiation 42 , 44 , 51 , 52 . The endogenous IFN-β induction by RANKL in osteoclasts is an important inhibitory feedback loop to maintain a balanced differentiation state 44 , 52 .…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Meanwhile, intrinsic anti-osteoclastogenic mechanisms mediated by negative regulators, such as interferon regulatory factor (IRF8), v-maf musculoaponeurotic fibrosarcoma oncogene family protein B (MafB) and differentially expressed in FDCP 6 homolog (Def6), provide "a braking system" to prevent excessive osteoclastogenesis and bone resorption. 6,[8][9][10][11][12][13][14][15][16] These mechanisms can interact with each other and form regulatory networks to coordinately control osteoclastogenesis. Identification of these networks will broaden and deepen our understanding of the mechanisms that control osteoclastogenesis and bone metabolism, and help establish optimal and potential novel therapeutic strategies.…”
Section: Introductionmentioning
confidence: 99%
“…Irisin increases cortical bone mass and its low levels are related to muscle atrophy and obesity[, 1, 2 while myostatin is a negative regulator of muscle growth and regeneration and has a direct role in osteoclastogenesis of inflammatory bone destruction[. 3,4 Objectives: To evaluate serum levels of irisin and myostatin and body composition of RA patients and controls. Methods: 122 female patients with RA, mean age 53 years, mean disease activity score (DAS28) 4.09, mean disease duration 11.2 years and mean body mass index 27.33 kg/m 2 were included.…”
mentioning
confidence: 99%